Koen Augustyns obtained his master's and PhD in pharmaceutical sciences at the KU Leuven, Belgium, in 1988 and 1992, respectively. After postdoctoral stays at the University of Antwerp, Belgium, and the University of Tübingen, Germany, he was appointed as professor of medicinal chemistry at the University of Antwerp, Belgium, in 1997. He is the dean of the Faculty of Pharmaceutical, Biomedical, and Veterinary Sciences. He is a leading medicinal chemistry authority in Europe focused on the therapeutic domains of cell death/survival, inflammation, and infectious diseases. His mission is to develop chemical tool compounds that are used in the characterization and validation of novel targets and that will lead to novel hit and lead compounds in drug discovery. He is a principal investigator of more than 60 national and international research projects. He is currently also the coordinator of the Integrated Training in Dry Eye Disease Drug Development (IT-DED3) European consortium. Since 2002, he has been the president of the Medicinal and Bioorganic Chemistry Division of the Royal Flemish Chemical Society (KVCV) in Belgium, and he served the European Federation for Medicinal Chemistry (EFMC) as secretary (2009–2013), president-elect (2014), president (2015–2017), and past president (2018–2019). He is a member of the Jury of the Prix Galien Belgium.